Clinical Trial

An Evaluation of Two PTSD Assessments in an Active Duty and Military Veteran Sample

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 23, 2025 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
Given the high prevalence of post-traumatic stress disorder (PTSD) in veterans and active duty military, the focus of this research study is to test the reliability of two new PTSD assessments, the Clinician Administered PTSD Scale for DSM-5 (CAPS-5) and the PTSD Symptom Scale Interview for DSM-5 (PSSI-5) and compare the results between the two new assessments and the previous "gold standard", the Clinician Administered PTSD Scale for DSM-IV (CAPS-IV). Biomarkers believed to be related to PTSD (e.g., biofluid biomarkers, cognitive and physiological markers, and neural activity as measured by EEG) will be collected to inform targeted interventions in specific groups of patients and other large-scale biomarker discovery efforts in the field. Participants will be 950 male and female active duty military and veterans ages 18 or older who have been exposed to at least one traumatic event.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2019-11-25; most recent amendment 2025-01-22.
Trial Details
NCT Number NCT04180930
Lead Sponsor U.S. Army Medical Research and Development Command
Conditions Stress Disorders, Post-Traumatic
Enrollment 950 participants
Start Date 2019-04-15
Primary Completion 2025-06-30 (estimated)
Study Completion 2025-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-01-23